documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
84 rows where docket_id = "FDA-2023-N-4225" sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, comment_start_date, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
document_type 3
agency_id 1
- FDA 84
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2023-N-4225-0133 | FDA | None FDA-2023-N-4225 | Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products; Withdrawal | Proposed Rule | Withdrawal | 2025-11-28T05:00:00Z | 2025 | 11 | 2025-11-28T05:00:00Z | 2025-11-28T19:47:58Z | 2025-21407 | 0 | 0 | 09000064b90a1ed0 | |
| FDA-2023-N-4225-0099 | FDA | None FDA-2023-N-4225 | Request for Extension from U.S. Chamber of Commerce | Other | Request for Extension | 2025-03-21T04:00:00Z | 2025 | 3 | 2025-03-21T04:00:00Z | 2025-03-21T13:56:27Z | 0 | 0 | 0900006486a08a9d | ||
| FDA-2023-N-4225-0100 | FDA | None FDA-2023-N-4225 | Request for Extension from Essential Minerals Association | Other | Request for Extension | 2025-03-21T04:00:00Z | 2025 | 3 | 2025-03-21T04:00:00Z | 2025-03-21T13:58:09Z | 0 | 0 | 0900006486a0bb00 | ||
| FDA-2023-N-4225-0083 | FDA | None FDA-2023-N-4225 | Memorandum re Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products (Proposed Rule) | Other | Memorandum | 2025-01-23T05:00:00Z | 2025 | 1 | 2025-01-23T05:00:00Z | 2025-01-23T20:44:28Z | 0 | 0 | 09000064868f192c | ||
| FDA-2023-N-4225-0084 | FDA | None FDA-2023-N-4225 | TAB A - Asbestos in Talc NPRM as Submitted to OMB | Supporting & Related Material | Background Material | 2025-01-23T05:00:00Z | 2025 | 1 | 2025-01-23T20:46:08Z | 0 | 0 | 09000064868f10ef | |||
| FDA-2023-N-4225-0087 | FDA | None FDA-2023-N-4225 | TAB B - Asbestos in Talc PRIA Track Changes | Supporting & Related Material | Background Material | 2025-01-23T05:00:00Z | 2025 | 1 | 2025-01-23T20:46:28Z | 0 | 0 | 09000064868f10f2 | |||
| FDA-2023-N-4225-0088 | FDA | None FDA-2023-N-4225 | TAB C - Asbestos in Talc NPRM as Cleared by OMB | Supporting & Related Material | Background Material | 2025-01-23T05:00:00Z | 2025 | 1 | 2025-01-23T20:46:34Z | 0 | 0 | 09000064868f10f3 | |||
| FDA-2023-N-4225-0086 | FDA | None FDA-2023-N-4225 | TAB B - Asbestos in Talc NPRM Track Changes | Supporting & Related Material | Background Material | 2025-01-23T05:00:00Z | 2025 | 1 | 2025-01-23T20:46:23Z | 0 | 0 | 09000064868f10f1 | |||
| FDA-2023-N-4225-0085 | FDA | None FDA-2023-N-4225 | TAB A - Asbestos in Talc PRIA as Submitted to OMB | Supporting & Related Material | Background Material | 2025-01-23T05:00:00Z | 2025 | 1 | 2025-01-23T20:46:17Z | 0 | 0 | 09000064868f10f0 | |||
| FDA-2023-N-4225-0089 | FDA | None FDA-2023-N-4225 | TAB C - Asbestos in Talc PRIA as Cleared by OMB | Supporting & Related Material | Background Material | 2025-01-23T05:00:00Z | 2025 | 1 | 2025-01-23T20:46:41Z | 0 | 0 | 09000064868f10f4 | |||
| FDA-2023-N-4225-0039 | FDA | None FDA-2023-N-4225 | Reference 37 Rosner DG Nondetected The Politics of Measurem in Talc 1971 1976 AJPH Vol 2019 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:53:04Z | 0 | 0 | 090000648688cadb | |||
| FDA-2023-N-4225-0046 | FDA | None FDA-2023-N-4225 | PRIA Footnote Reference 1 Updating Value per Statistical Life (VSL) Estimates for Inflation and Changes in Real Income | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:53:46Z | 0 | 0 | 090000648688cafa | |||
| FDA-2023-N-4225-0056 | FDA | None FDA-2023-N-4225 | PRIA Reference 8 Passport Beauty and Personal Care in the US | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:54:50Z | 0 | 0 | 090000648688cb05 | |||
| FDA-2023-N-4225-0002 | FDA | None FDA-2023-N-4225 | List of references 12 11 2024 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:49:21Z | 0 | 0 | 090000648688caae | |||
| FDA-2023-N-4225-0028 | FDA | None FDA-2023-N-4225 | Reference 26 - Lowers H -Tabulation of Asbestos Related Terminology 2002 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:51:58Z | 0 | 0 | 090000648688cad1 | |||
| FDA-2023-N-4225-0029 | FDA | None FDA-2023-N-4225 | Reference 27 - Campbell WJ Selected Silicate Minerals and Their Asbestiform Varieties US Bureau of Mines Information Circular 8751- 1977 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:52:04Z | 0 | 0 | 090000648688cad2 | |||
| FDA-2023-N-4225-0043 | FDA | None FDA-2023-N-4225 | Reference 41 USP-NF General Chapter Prospectus 1901_ Theory and Practices of Asbestos Detection in PHarmaceutical Talc 2021 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:53:29Z | 0 | 0 | 090000648688cadf | |||
| FDA-2023-N-4225-0059 | FDA | None FDA-2023-N-4225 | PRIA Reference 11 Malignant Mesothelioma and Its Non-Asbestos Causes | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:55:06Z | 0 | 0 | 090000648688cb08 | |||
| FDA-2023-N-4225-0018 | FDA | None FDA-2023-N-4225 | Reference 16 Translocation of inhaled asbestos fibers from the lung to other tissues.pdf Suzuki Y 1991 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:50:54Z | 0 | 0 | 090000648688cac8 | |||
| FDA-2023-N-4225-0052 | FDA | None FDA-2023-N-4225 | PRIA Reference 4 Method J 4-1 Asbestiform Amphibole Minerals in Cosmetic Talc | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:54:26Z | 0 | 0 | 090000648688cb00 | |||
| FDA-2023-N-4225-0054 | FDA | None FDA-2023-N-4225 | PRIA Reference 6 White Paper IWGACP Scientific Opinions on Testing Methods for Asbestos in Cosmetic Products Containing Talc | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:54:39Z | 0 | 0 | 090000648688cb03 | |||
| FDA-2023-N-4225-0004 | FDA | None FDA-2023-N-4225 | Reference 2 Where is Asbestos Found ATSDR - Naturally Occurring Asbestos | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:49:33Z | 0 | 0 | 090000648688cab0 | |||
| FDA-2023-N-4225-0019 | FDA | None FDA-2023-N-4225 | Reference 17 Fitzgerald Comparing Historical and Recent Accelerated Concerns Regarding Asbestos in Talc 2021 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:51:00Z | 0 | 0 | 090000648688cac9 | |||
| FDA-2023-N-4225-0021 | FDA | None FDA-2023-N-4225 | Reference 19 FDA In Brief_ FDA Releases Final Report of Talc-containing cosmetic products tested for asbestos | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:51:12Z | 0 | 0 | 090000648688cacb | |||
| FDA-2023-N-4225-0051 | FDA | None FDA-2023-N-4225 | PRIA Reference 3 Asbestos in Commercial Cosmetic Talcum Powder as a Cause of Mesothelioma in Women | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:54:21Z | 0 | 0 | 090000648688caff | |||
| FDA-2023-N-4225-0053 | FDA | None FDA-2023-N-4225 | PRIA Reference 5 The U.S. Pharmacopeial Convention Revision Bulletin Talc | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:54:32Z | 0 | 0 | 090000648688cb01 | |||
| FDA-2023-N-4225-0072 | FDA | None FDA-2023-N-4225 | PRIA Reference 24 Critical Review of the Association Between Perineal Use of Talc Powder and Risk of Ovarian Cancer | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:56:17Z | 0 | 0 | 090000648688cb18 | |||
| FDA-2023-N-4225-0074 | FDA | None FDA-2023-N-4225 | PRIA Reference 26 Some Pitfalls of Practical Benefit-Cost Analys | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:56:28Z | 0 | 0 | 090000648688cb1a | |||
| FDA-2023-N-4225-0001 | FDA | None FDA-2023-N-4225 | Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products | Proposed Rule | Notice of Proposed Rulemaking (NPRM) | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-27T05:00:00Z | 2025-03-28T03:59:59Z | 2025-03-29T01:00:19Z | 2024-30544 | 0 | 0 | 090000648689150a |
| FDA-2023-N-4225-0006 | FDA | None FDA-2023-N-4225 | Reference 4 Segrave Overview of the Geology of Cosmetic Talc Formation 2021 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:49:45Z | 0 | 0 | 090000648688cab2 | |||
| FDA-2023-N-4225-0008 | FDA | None FDA-2023-N-4225 | Reference 6 Toxicological Review of Libby Amphibole Asbestos EPA IRIS 2014 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:49:57Z | 0 | 0 | 090000648688cab4 | |||
| FDA-2023-N-4225-0010 | FDA | None FDA-2023-N-4225 | Reference 8 Toxicological Profile for Asbestos ATSDR 2001 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:50:08Z | 0 | 0 | 090000648688cab6 | |||
| FDA-2023-N-4225-0023 | FDA | None FDA-2023-N-4225 | Reference 21 Block Stimuli to the Revision Process Modernization of Asbestos Testing in Talc USP PF 40 4 2014 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:51:24Z | 0 | 0 | 090000648688caba | |||
| FDA-2023-N-4225-0017 | FDA | None FDA-2023-N-4225 | Reference 15 Asbestos exposure and ovarian fiber burden. | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:50:49Z | 0 | 0 | 090000648688cac7 | |||
| FDA-2023-N-4225-0041 | FDA | None FDA-2023-N-4225 | Reference 39 USP CN Talc Detection of Asbestos in Pharmace Talc 1901 Theory and Practice of Asbestos Detection in Pharmace 2023.. | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:53:18Z | 0 | 0 | 090000648688cadd | |||
| FDA-2023-N-4225-0049 | FDA | None FDA-2023-N-4225 | PRIA Reference 1 National Toxicology Report on Carcinogens | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:54:10Z | 0 | 0 | 090000648688cafd | |||
| FDA-2023-N-4225-0057 | FDA | None FDA-2023-N-4225 | PRIA Reference 9 Talc and Pyrophyllite Mineral Commodity Summary | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:54:54Z | 0 | 0 | 090000648688cb06 | |||
| FDA-2023-N-4225-0061 | FDA | None FDA-2023-N-4225 | PRIA Reference 13 Costs of Medical Care for Mesothelioma | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:55:17Z | 0 | 0 | 090000648688cb0d | |||
| FDA-2023-N-4225-0064 | FDA | None FDA-2023-N-4225 | PRIA Reference 16 Cost of Care for the Initial Management of Ovarian Cancer | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:55:34Z | 0 | 0 | 090000648688cb10 | |||
| FDA-2023-N-4225-0066 | FDA | None FDA-2023-N-4225 | PRIA Reference 18 Guidelines for Regulatory Impact Analysis | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:55:45Z | 0 | 0 | 090000648688cb12 | |||
| FDA-2023-N-4225-0070 | FDA | None FDA-2023-N-4225 | PRIA Reference 22 Douching and Genital Talc Use Patterns of Use and Reliability of Self-reported Exposure | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:56:06Z | 0 | 0 | 090000648688cb16 | |||
| FDA-2023-N-4225-0009 | FDA | None FDA-2023-N-4225 | Reference 7 Filetti et al Update of in vitro in vivo and ex vivo fluoro edenite effects of malignant mesothelioma 2020 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:50:02Z | 0 | 0 | 090000648688cab5 | |||
| FDA-2023-N-4225-0015 | FDA | None FDA-2023-N-4225 | Reference 13 IWGACP Appendices to White Paper January 13 2022 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:50:38Z | 0 | 0 | 090000648688cac5 | |||
| FDA-2023-N-4225-0067 | FDA | None FDA-2023-N-4225 | PRIA Reference 19 USP's Iterative Approach to Standards Development and the Emerging Standards | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:55:50Z | 0 | 0 | 090000648688cb13 | |||
| FDA-2023-N-4225-0014 | FDA | None FDA-2023-N-4225 | Reference 12 Asbestos hazards-and-safe-practice-for-clear-up-after-tsunami. 2006 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:50:33Z | 0 | 0 | 090000648688cac4 | |||
| FDA-2023-N-4225-0033 | FDA | None FDA-2023-N-4225 | Reference 31 - COPYRIGHT International Organization for Standardization ISO 22262-1-2012 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:52:27Z | 0 | 0 | 090000648688cad6 | |||
| FDA-2023-N-4225-0036 | FDA | None FDA-2023-N-4225 | Reference 34 - CIR Expert Panel Meeting March 18-19 2013 - Safety Assessment of Talc as Used in Cosmetics 2013 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:52:47Z | 0 | 0 | 090000648688cad8 | |||
| FDA-2023-N-4225-0045 | FDA | None FDA-2023-N-4225 | Talc PRIA Reference List | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:53:41Z | 0 | 0 | 090000648688caf9 | |||
| FDA-2023-N-4225-0062 | FDA | None FDA-2023-N-4225 | PRIA Reference 14 Lung Cancer Costs by Treatment Strategy and Phase of Care Among Patients Enrolled in Medicare | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:55:23Z | 0 | 0 | 090000648688cb0e | |||
| FDA-2023-N-4225-0068 | FDA | None FDA-2023-N-4225 | PRIA Reference 20 Consolidated Financial Statements and Report of Independent Certified Public Accountants United States Pharmacopeial Convention and Subsidia | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:55:56Z | 0 | 0 | 090000648688cb14 | |||
| FDA-2023-N-4225-0013 | FDA | None FDA-2023-N-4225 | Reference 11 Asbestos - Overview _ Occupational Safety and Health Administration | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:50:27Z | 0 | 0 | 090000648688cac3 | |||
| FDA-2023-N-4225-0022 | FDA | None FDA-2023-N-4225 | Reference 20 Millette Procedure for the Analysis of Talc for Asbestos 2015 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:51:18Z | 0 | 0 | 090000648688cacc | |||
| FDA-2023-N-4225-0025 | FDA | None FDA-2023-N-4225 | Reference 23 Peer review Report External Peer Review Comments and FDA Responses 2024 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:51:36Z | 0 | 0 | 090000648688cace | |||
| FDA-2023-N-4225-0031 | FDA | None FDA-2023-N-4225 | Reference 29 Baumann Asbestos is not just asbestos_ an unrecognised health hazard 2013 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:52:16Z | 0 | 0 | 090000648688cad4 | |||
| FDA-2023-N-4225-0037 | FDA | None FDA-2023-N-4225 | Reference 35 Talc _ USP-NF Compendial Notices Intent to Revise Talc USP Monograph Asbestos Test Method 2020 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:52:52Z | 0 | 0 | 090000648688cad9 | |||
| FDA-2023-N-4225-0044 | FDA | None FDA-2023-N-4225 | Reference 42 Preliminary Regulatory Impact Analysis Asbestos in Talc PRIA | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:53:35Z | 0 | 0 | 090000648688caf8 | |||
| FDA-2023-N-4225-0050 | FDA | None FDA-2023-N-4225 | PRIA Reference 2 A Review of Human Carcinogens Part C Metals Arsenic Dusts and Fibres | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:54:16Z | 0 | 0 | 090000648688cafe | |||
| FDA-2023-N-4225-0058 | FDA | None FDA-2023-N-4225 | PRIA Reference 10 Asbestos Contamination in Talc-Based Cosmetics An Invisible Cancer Risk | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:55:00Z | 0 | 0 | 090000648688cb07 | |||
| FDA-2023-N-4225-0069 | FDA | None FDA-2023-N-4225 | PRIA Reference 21 Sunscreen Drug Formulations for Over-the-Counter Human Use | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:56:01Z | 0 | 0 | 090000648688cb15 | |||
| FDA-2023-N-4225-0073 | FDA | None FDA-2023-N-4225 | PRIA Reference 25 Perineal Use of Talc and Risk of Ovarian Cancer | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:56:23Z | 0 | 0 | 090000648688cb19 | |||
| FDA-2023-N-4225-0003 | FDA | None FDA-2023-N-4225 | Reference 1 Ultramafic hosted talc magnesite deposits 2006 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:49:27Z | 0 | 0 | 090000648688caaf | |||
| FDA-2023-N-4225-0011 | FDA | None FDA-2023-N-4225 | Reference 9 IARC_Monograph_Asbestos.2012 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:50:14Z | 0 | 0 | 090000648688cab7 | |||
| FDA-2023-N-4225-0034 | FDA | None FDA-2023-N-4225 | Reference 32 - International Organization for Standardization ISO 10312-2019 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:52:33Z | 0 | 0 | 090000648688cabd | |||
| FDA-2023-N-4225-0027 | FDA | None FDA-2023-N-4225 | Reference 25 Miller E. A review of the mesotheliogenic potency of cleavage fragments found in talc | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:51:52Z | 0 | 0 | 090000648688cad0 | |||
| FDA-2023-N-4225-0030 | FDA | None FDA-2023-N-4225 | Reference 28 Van Gosen - A USGS Study of Talc Deposits and Associated Amphibole ....Southern Death Valley Region Californina 2004 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:52:09Z | 0 | 0 | 090000648688cad3 | |||
| FDA-2023-N-4225-0040 | FDA | None FDA-2023-N-4225 | Reference 38 USP Talc Absence of Asbestos Test method Official May 1 2022 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:53:12Z | 0 | 0 | 090000648688cadc | |||
| FDA-2023-N-4225-0042 | FDA | None FDA-2023-N-4225 | Reference 40 General Chapter Prospectus 901_ Detection of Asbestos in Pharmaceutical Talc 2021 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:53:23Z | 0 | 0 | 090000648688cade | |||
| FDA-2023-N-4225-0063 | FDA | None FDA-2023-N-4225 | PRIA Reference 15 Treatment Survival and Costs of Laryngeal Cancer Care in the Elderly | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:55:28Z | 0 | 0 | 090000648688cb0f | |||
| FDA-2023-N-4225-0065 | FDA | None FDA-2023-N-4225 | PRIA Reference 17 Recall Cost Cast Studies | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:55:39Z | 0 | 0 | 090000648688cb11 | |||
| FDA-2023-N-4225-0071 | FDA | None FDA-2023-N-4225 | PRIA Reference 23 The Environmental Injustice of Beauty Framing Chemical Exposures from Beauty Products as a Health Disparities Concern | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:56:12Z | 0 | 0 | 090000648688cb17 | |||
| FDA-2023-N-4225-0024 | FDA | None FDA-2023-N-4225 | Reference 22 Interagency Workgroup for Asbestos in Consumer Products IWGACP- White Paper 2022 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:51:29Z | 0 | 0 | 090000648688cacd | |||
| FDA-2023-N-4225-0026 | FDA | None FDA-2023-N-4225 | Reference 24 Public Meeting on Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:51:41Z | 0 | 0 | 090000648688cacf | |||
| FDA-2023-N-4225-0038 | FDA | None FDA-2023-N-4225 | Reference 36 ISO IEC Guide 2 2004. Standardization and related activities General vocabulary 2004 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:52:59Z | 0 | 0 | 090000648688cada | |||
| FDA-2023-N-4225-0005 | FDA | None FDA-2023-N-4225 | Reference 3 Virta Asbestos Geology Mineralogy Mining and Uses 2002 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:49:39Z | 0 | 0 | 090000648688cab1 | |||
| FDA-2023-N-4225-0007 | FDA | None FDA-2023-N-4225 | Reference 5 Asbestos. In Report on Carcinogens Fiftheenth Edition 2021 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:49:51Z | 0 | 0 | 090000648688cab3 | |||
| FDA-2023-N-4225-0016 | FDA | None FDA-2023-N-4225 | Reference 14 Ingested mineral fibers elimination in human urine Science 204 195-8 1979 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:50:44Z | 0 | 0 | 090000648688cac6 | |||
| FDA-2023-N-4225-0020 | FDA | None FDA-2023-N-4225 | Reference 18 FDA Talc Previous Activity | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:51:06Z | 0 | 0 | 090000648688caca | |||
| FDA-2023-N-4225-0035 | FDA | None FDA-2023-N-4225 | Reference 33 IMA Amphibole Supergroup Mineral information data and localities | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:52:39Z | 0 | 0 | 090000648688cad7 | |||
| FDA-2023-N-4225-0048 | FDA | None FDA-2023-N-4225 | PRIA Footnote Reference 3 A Population-level Approach to Distributional Weighting | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:53:57Z | 0 | 0 | 090000648688cafc | |||
| FDA-2023-N-4225-0060 | FDA | None FDA-2023-N-4225 | PRIA Reference 12 Under-Reporting of Adverse Drug Reactions A Systematic Review | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:55:12Z | 0 | 0 | 090000648688cb09 | |||
| FDA-2023-N-4225-0012 | FDA | None FDA-2023-N-4225 | Reference 10 Asbestos Selected Cancers NAS 2006 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:50:20Z | 0 | 0 | 090000648688cac2 | |||
| FDA-2023-N-4225-0032 | FDA | None FDA-2023-N-4225 | Reference 30 - National Institute for Occupational Safety and Health 2011 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:52:21Z | 0 | 0 | 090000648688cad5 | |||
| FDA-2023-N-4225-0047 | FDA | None FDA-2023-N-4225 | PRIA Footnote Reference 2 Circular A-4 | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:53:52Z | 0 | 0 | 090000648688cafb | |||
| FDA-2023-N-4225-0055 | FDA | None FDA-2023-N-4225 | PRIA Reference 7 Latent Period for Malignant Mesothelioma of Occupational Origin | Supporting & Related Material | Background Material | 2024-12-27T05:00:00Z | 2024 | 12 | 2024-12-30T02:54:44Z | 0 | 0 | 090000648688cb04 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;